Search - tctmd.com

Displaying 161 - 180 of 221

Sort: Relevancy | Date

Presentation

Paclitaxel-Coated Balloon Catheter Compared With DES for DES Restenosis in Routine Clinical Practice

Presenter: S Habara

March 01, 2015

News Features

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

L.A. McKeown

January 28, 2015

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2014

Caitlin E. Cox

January 12, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

News Conference News TCT 2014

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

September 13, 2014

News Industry News

Boston Scientific Receives CE Mark For Agent™ Drug-Coated Balloon

July 23, 2014

News Industry News

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

July 14, 2014

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

News Daily News

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

L.A. McKeown

June 17, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

Presentation EuroPCR 2014

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Presenter: Jos? Ram?n L?pez-M?nguez

May 20, 2014

Presentation CIT 2014

Clinical outcomes of paclitaxel coated balloon angioplasty in an unselected patient population with drug eluting stent in-stent restenosis: Results from the French GARO Registry

Presenter: M Bedossa

March 22, 2014

Presentation

Preliminary Results from PATENT-C: A RCT Comparing A Paclitaxel-Coated Scoring Balloon to a Standard Balloon in Coronary ISR

Presenter: Gary Gershony

December 01, 2013

Presentation TCT 2013

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Presenter: Michael Joner

October 31, 2013

News Conference News TCT 2013

Drug-coated Balloons May Become Standard of Care in ISR

October 31, 2013

Advertisement

Paclitaxel-Coated Balloon Catheter Compared With DES for DES Restenosis in Routine Clinical Practice

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

TCTMD’s Top 10 Most Popular News Stories for 2014

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

Boston Scientific Receives CE Mark For Agent™ Drug-Coated Balloon

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Clinical outcomes of paclitaxel coated balloon angioplasty in an unselected patient population with drug eluting stent in-stent restenosis: Results from the French GARO Registry

Preliminary Results from PATENT-C: A RCT Comparing A Paclitaxel-Coated Scoring Balloon to a Standard Balloon in Coronary ISR

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Drug-coated Balloons May Become Standard of Care in ISR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content